Purpose Beta-2 adrenoceptor agonistic drugs like ritodrine have been the reference tocolytic drugs, but are associated with cardiovascular side-effects. Atosiban, a newer drug, is a competitive antagonist of oxytocin and has been claimed to have fewer cardiovascular side effects. Until now, there has mainly been a subjective reporting of adverse reactions and few objective cardiovascular data. Evaluation of the acute effects of therapeutic doses of ritodrine and atosiban compared with placebo on cardiac function, large artery properties, blood pressure, and resistance vessels.
Introduction
Preterm labor is the most frequently reported cause of perinatal morbidity and mortality in the Western world [1] . Tocolytic medication can postpone delivery [2] . Beta-2 adrenoceptor agonistic drugs have been the reference tocolytic drugs in most countries [1, 3] . Their efficacy in prolonging pregnancy compared with placebo is proven, although no benefit in neonatal morbidity or mortality has been demonstrated. Beta-mimetics are not highly selective and have many contraindications. Sideeffects are frequent because of beta-1 and -2 adrenoceptor agonistic cardiovascular effects. Even serious complications such as pulmonary oedema and maternal death, though rare, have been reported [4] .
Oxytocin receptor blockers are a new class of tocolytic drugs. The oxytocin antagonist atosiban has fewer side effects than beta-agonists [5] . However, it is no more effective than ritodrine and the benefit of safety has to be balanced against that of cost [6, 7] . A study of Ferriols et al. revealed that the cost-effectiveness obtained with the protocol including ritodrine as first-choice drug was three times less than when atosiban was used. In pregnant women in whom the likelihood of developing acute pulmonary edema is high, or when cardiovascular risk is high (e.g., preeclampsia, cardiomyopathies, cardiovascular syndromes), atosiban may be an appropriate alternative option [8] . Although large studies using atosiban have been performed [4, 9] , there is mainly a subjective reporting of adverse reactions during infusion, and objective data with regard to cardiovascular effects are scarce.
To the best of our knowledge, the hemodynamic effects on the heart and on the micro-and macrocirculation have not been studied before in a single study [10] . We evaluated the acute effects of therapeutic doses of ritodrine and atosiban on blood pressure, cardiac function, microcirculation (total peripheral resistance), and macrocirculation (large artery stiffness) in healthy non-pregnant female volunteers.
Materials and methods

Subjects
Twenty healthy non-pregnant female volunteers, either nonsmokers or controlled smokers (≤10 cigarettes per day), with adequate non-uteral contraception, were recruited from the local population. All participants gave written informed consent upon screening, organized within the 2 weeks before the first planned drug administration. They were apparently healthy (no cardiovascular disease [arrhythmias included], obstructive lung disease, chronic kidney disease or diabetes mellitus). Breastfeeding women or women with a severe addiction were excluded.
Subjects were asked not to eat and smoke, and not to drink caffeine-containing beverages for at least 3 h before and during the measurements. They also had to refrain from drinking alcohol for at least 10 h before measurements [11] .
Design
A double-blind, randomized trial was carried out at the Drug Research Unit Ghent of the Ghent University Hospital, Belgium. The study was approved by the Ethics Committee of Ghent University and conducted according to ICH Good Clinical Practice and the Declaration of Helsinki (last amended in 2008 in Seoul).
Twenty female volunteers were given atosiban (Tractocile®, Ferring, Sweden) and placebo (glucose 5%) intravenously, in a random order. Eight of them were randomly chosen to also receive ritodrine (PrePar®, Eumedica, Belgium) in a single-blind manner. The effects of drugs were compared after 95 min of infusion when kinetic steady state was reached for atosiban and ritodrine, being 15 min after starting the highest dose (400 μg/min) of ritodrine. Hemodynamic measurements were made by one investiga-tor with the subjects in a supine position and under standardized conditions (derived from the Task Force III, clinical applications for arterial stiffness [11] ) including a temperature controlled room (22±1°C).
Medication
Each medication and placebo were infused for 120 min. Both atosiban and ritodrine were given with glucose (5%) as vehiculum. Atosiban was given at a constant dose of 300 μg/ min at a constant infusion rate of 0.4 ml/min. Ritodrine was given in a dose escalation scheme starting with a dose of 100 μg/min and gradually upgraded to a dose of 400 μg/min. The infusion rate varied with each dosing step (from 0.23 to 0.53 ml/min). Glucose (5%) was given as placebo at a constant infusion rate of 0.4 ml/min. Dosing was based on previous studies using atosiban or ritodrine [1, [12] [13] [14] [15] and on the manufacturers' prescriptions. During each period, the subjects received a total volume of 48 ml.
Stopping criteria for dosing were: a heart rate increase above 75% of the age-based maximal heart rate or blood pressure changes from baseline of more than 30 mmHg for systolic (SBP) and 15 mmHg for diastolic blood pressure (DBP); an SBP above 180 mmHg or less than 90 mmHg and DBP more than 110 mmHg. The infusion was also ended if the subject suffered intolerable side effects.
Measurements
Brachial blood pressure and heart rate Semi-recumbent brachial SBP and DBP and heart rate (HR) were recorded at the right upper arm opposite to the arm with the intravenous infusion line with a validated semiautomated oscillometric device (OMRON 705IT, OMRON Healthcare, Hoofddorp, The Netherlands) [16] . Mean arterial pressure (MAP) was calculated by adding 40% of the pulse pressure (PP) to the measured DBP [17] .
Cardiac output
Cardiac output (CO) was measured using echocardiography (AU5, Esaote, Genoa, Italy). Measurements were performed in the left lateral position. Aortic diameter (D) was measured at least three times using pulsed ultrasound at 2.5 MHz from a standard two-dimensional long-axis parasternal view at the site of the aortic annulus; the median of these readings was used in the subsequent calculations. Aortic blood velocity profiles (at least five beats) were measured across the aortic valve with continuous ultrasound using an apical window. Stroke volume (SV) was calculated from aortic cross-sectional area (CSA ao ) multiplied by the flow velocity integral (FVI).
CSA ao was calculated as pD2 4 =
Heart rate was determined from the duration of the cardiac cycle on the FVI [18] . In our hands, the reproducibility of the aortic diameter and the FVI expressed as a coefficient of variation were 4% and 6% respectively. To relate the heart function to body size, CO and SV were divided by the body surface area (BSA), which was calculated by the Dubois and Dubois formula [19] to obtain the cardiac index (CI) and the stroke index (SI).
Microcirculation
The effects on the microcirculation were estimated using the total peripheral resistance index (TPRI), which was calculated as MAP divided by the CI.
Macrocirculation
Large artery wall properties were assessed for the aorta using carotid-femoral pulse wave velocity (PWV), and local distensibility and compliance were measured at the right common carotid artery (CCA) and right common femoral artery (CFA).
The PWV was measured using a Sphygmocor® (AtCor Medical, Sydney, Australia) system [20, 21] . Surface distance between the two recording sites was measured in the supine position using an anthropometer and the supra-sternal notch (SSN) as a reference point: the distance CCA to SSN was subtracted from the distance SSN to CFA. Arterial cross-sectional compliance (CC), a measure of buffering capacity and distensibility coefficient (DC), a measure of elasticity, were calculated as follows [22] :
Where ΔA is the systolic-diastolic change in arterial cross-section at a given location; ΔP is the local pulse pressure (PP) at a given location; D s is the arterial diameter at end-systole; D d is the arterial diameter at end-diastole; A d is the arterial cross-section at end-diastole.
Arterial diameter distension waveforms were assessed with a wall-tracking vascular echoscanner (Wall Track System, Esaote, Genoa, Italy) [23] equipped with a 7.5-10 MHz linear array. Wall motion was tracked at the interface between the media and adventitia at both (near and far) walls, 1-2 cm proximal to the bifurcation of the CCA and the CFA. Per location, the median of three recordings, each lasting for 5-6 s, was used for data analysis. In our hands, reproducibility of diameter and displacement expressed as a coefficient of variation was 4% and 6% for the CCA and 3% and 7% for CFA respectively. Femoral and carotid pressure waveforms (PWFs) were recorded non-invasively with a Sphygmocor® (AtCor Medical, Sydney, Australia) [24] . To obtain local blood pressure at the CCA and CFA, calibration of the recorded PWFs was required. Calibration is based on the validated assumption that DBP and MAP remain constant throughout the large arteries, while SBP and PP (the difference between SBP and DBP) change [25] .
Additionally, isobaric wall properties (expressed as DC ISO and CC ISO ) were calculated for each subject. The diameter and pressure waveforms were time-aligned using the peak as a reference point. The resulting diameter-time recordings at CCA and CFA were analyzed off-line using Matlab®. In each subject, CC and DC were calculated over the blood pressure interval common in each treatment period (the highest DBP and the lowest SBP). In this way, the direct drug-induced changes in distensibility and compliance could be differentiated from the changes resulting from a change in blood pressure.
Data analysis
The median of three measurements was used for data analysis. Statistics were obtained using IBM® SPSS® version 18 (SPSS, Chicago, IL, USA). Demographic differences between study groups were analyzed using the non-parametric Mann-Whitney U test.
The cardiovascular effects were analyzed by the nonparametric Kruskal-Wallis test. If statistically different (p<0.1), a Mann-Whitney U test was run for a two-point comparison.
Results
Demographic data
At study entry, the subgroup of 8 subjects also receiving ritodrine did not differ statistically from the whole group (n=20; Table 1 ). All subjects received the total amount of the planned dose, which was 300 μg/min for atosiban and 400 μg/min as the highest dose for ritodrine. Most of the adverse drug events were seen during ritodrine exposure, no adverse events happened during placebo or atosiban infusion (Table 2) .
Hemodynamic data
The effects of the tocolytic drugs compared with placebo on cardiac function, blood pressure, and micro-and macrocirculation are shown in Table 3 .
The CI with ritodrine increased significantly versus placebo (79%). This was due to an increase in heart rate (91%), while the SI did not change. Administration of atosiban did not change the cardiac index, stroke index or heart rate versus placebo, nor did it change blood pressure or TPRI. In contrast, ritodrine increased systolic blood pressure and heart rate, decreased the diastolic blood pressure, while the mean arterial pressure did not change statistically. Ritodrine also decreased the TPRI by 48%.
The diameters of the CCA and the CFA were not influenced by either treatment. Ritodrine had significantly increased DC and CC of the CCA (62% and 83% respectively) and of the more muscular CFA (59% and 33% respectively). Since changes in blood pressure can passively change arterial wall properties, direct tocolytic drug effects were assessed under isobaric conditions. Except for DC ISO of the CFA, which tended to increase (55%), all isobaric parameters remained significantly increased with ritodrine (DC ISO and CC ISO of the CCA 61% and 83% respectively, and CC ISO of the CFA 28%). Atosiban had no significant effects on the arterial wall properties of the CCA and CFA. The PWV was not influenced by ritodrine or atosiban, but was positively correlated by MAP during ritodrine infusion. Re-analysis with the adjusted parameter did not influence the outcome.
Discussion
To the best of our knowledge, this is the first placebocontrolled, randomized study investigating the effects of ritodrine and atosiban on cardiac function, and on microand macrocirculation in the same study [26] [27] [28] [29] . Ritodrine had considerable effect, while atosiban showed no significant influence on the cardiovascular system. Like other studies, the CI increased with ritodrine [30, 31] and remained unchanged with atosiban [32] . In the present study the increased cardiac output with ritodrine was predominantly due to a beta 1 -mediated increase in heart rate, while stroke index (SI) remained unchanged. The latter is not in accordance with other data where an increased SV was found [30, 31] . These studies refer to data in pregnant women who already had a decreased SV because of the pregnant uterus [33] . The effect of ritodrine on SV and SI was the net result of different effects:
1. The direct betareceptor mediated increased cardiac contractility 2. The decrease in afterload by the decrease in TPRI would increase SI 3. Venous dilatation [30] had the opposite effect on SI by a decrease in cardiac filling and cardiac contractility
The decrease in TPRI (almost 50%) with ritodrine is in line with other data [30, 31] and is due to beta 2 -mediated vasodilatation with ritodrine. The "flushing" in some subjects with ritodrine was reflecting this vasodilatation. Ritodrine had effects on both the arterial wall properties of the CCA and the CFA. These effects were also present under isobaric conditions, indicating a direct (acute) effect of ritodrine on the arterial walls of the CCA and CFA. This effect is at least in part due to smooth muscle relaxation in the arterial wall and is in line with the in vitro observation on the umbilical artery by Dennedy et al. [34] The considerable effect on the less muscular CCA is somewhat surprising and is correlated with the strong vasodilation, although an ancillary acute mechanism cannot fully be excluded. In contrast, stiffness of the more elastic aorta, measured by pulse wave velocity, did not change with ritodrine. However, a small direct effect hidden by the indirect effects of changes in blood pressure and heart rate could not be expelled [35] . We tested this hypothesis by correlating PWV with its two main confounders, MAP and HR. Only the MAP was positively correlated with PWV, but did not change the outcome after correction for it (from 6.08 m/s to 6.07 m/s).
The present study was carried out in non-pregnant women. It is not clear whether the present results in nonpregnant women can be fully extrapolated to pregnant women. Physiological changes during pregnancy like an increase in cardiac output, a decrease in peripheral resistance [33, 36] , and modulation of oxytocin receptors during pregnancy [37, 38] may alter the magnitude of the pharmacodynamic effects. On the other hand, pain and stress during premature labor may also confound the effects of tocolytic drugs. To elucidate these issues, this study would ideally be performed during late pregnancy in women with no signs of premature labor. However, this may be difficult because of ethical issues.
Some data analyses were hampered by the small study population on ritodrine. However, the cardiovascular effects observed with ritodrine were large; thus, the main outcomes are not likely to be influenced by this small sample size.
Ritodrine has a considerable effect on the cardiovascular system. Since HR and CI are almost doubled in comparison Twenty non-pregnant, healthy female volunteers received atosiban and placebo in a double-blinded manner, whereas 8 of them also received ritodrine in a single-blinded manner. All data are expressed as mean±standard deviation, except for smoking history BMI, body mass index); SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; bpm, beats per minute with placebo, it may not be the preferred drug in patients at risk of cardiac disorders, as the cardiovascular effects of beta-agonists could exacerbate underlying cardiovascular disease [30, 31] . Also, very divergent effects of ritodrine have been published like the effects on SBP starting from systolic hypotension and ending with an increased SBP, as in the present study [31, 39, 40] . Potential beneficial effects of ritodrine may be the higher arterial elasticity and buffering capacity and the lower peripheral resistance. These effects are largely due to a beta 2 -adrenergic-mediated increase in endothelial nitric oxide release [41] , which may alleviate peripheral vasoconstriction due to endothelial dysfunction in cases of gestational hypertension or other vascular complications during pregnancy. However, a potential beneficial effect of ritrodrine may not be overestimated as this drug is only given for a short period of time and as the improved beta-adrenergic-mediated endothelial NO release may not be present in subjects with an impaired NO pathway [41] . The latter might be the case in pregnancy, since stimulated nitric oxide release was reduced in normal pregnancy and preeclampsia, while vascular smooth muscle sensitivity to nitric oxide was not altered [42] . Moreover, in hypertensive pregnancies, the circulating components of the RAAS (renin-angiotensin-aldosterone system) are decreased and since betaagonists increase the outflow of the RAAS [31, 43, 44] , this could aggravate endothelial dysfunction. Because of the lowering of the diastolic blood pressure, ritodrine may compromise the flow toward the placenta [45, 46] . In addition, the potential beneficial vascular effects of ritodrine appear to be counterbalanced by its detrimental cardiac effects, which impels caution for the use of ritodrine in cardiovascular-complicated pregnancies.
Atosiban, on the other hand, was shown to have no significant cardiovascular effects, which is in agreement with previous findings. Our data add substantial information by using more complex cardiovascular measurements. However, the high cost of atosiban and the similar tocolytic effectiveness compared with ritodrine [5, 47] , makes it a non-cost-effective alternative for widespread use. 
Conclusion
In conclusion, the present study shows potentially beneficial vascular effects of ritodrine. These effects appear to be counterbalanced by the detrimental cardiac effects. There are no clinically relevant effects of atosiban on the cardiovascular system. Since the tocolytic effectiveness is the same, atosiban may be a good alternative to ritodrine in pregnant women with cardiovascular complications.
